Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between the ages of 18 to 55 years, inclusive~* Diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual, Edition 4, text revision (DSM-IV-TR) criteria~* Subjects who are deemed valid by the State, Assessability, Face, Ecological, and Rule (SAFER) interview~* Subjects who are otherwise healthy on the basis of their physical examination~Exclusion Criteria:~* Subjects who have an improvement in their total Positive and Negative Syndrome Scale (PANSS) score of 20% or greater between the initial screening visit and the first day of treatment.~* Subjects taking daily oral risperidone at a dose ≥ 6 mg/day~* Subjects who have received a depot antipsychotic within 120 days of screen~* Subjects with treatment resistant schizophrenia, as judged by the investigator, who have been treated with antipsychotics for adequate durations and with adequate dosages.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- RBP-7000 90 mg (Type: EXPERIMENTAL): Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 90 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
- RBP-7000 120 mg (Type: EXPERIMENTAL): Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 120 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
- Placebo (Type: PLACEBO_COMPARATOR): Risperidone tablets given during the screening period to check for sensitivity. Placebo administered by subcutaneous injection on Days 1 and 29 for a total of two injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).